USD 0.0
(0.0%)
Year | Gross Profit | Gross Profit Growth |
---|---|---|
2021 | -488.31 Thousand USD | 0.0% |
2020 | - USD | 0.0% |
2019 | - USD | 0.0% |
2018 | - USD | 0.0% |
2017 | - USD | 0.0% |
2016 | - USD | 0.0% |
2015 | - USD | 0.0% |
2014 | - USD | 0.0% |
2013 | - USD | 0.0% |
2012 | - USD | -100.0% |
2011 | 8.79 Billion USD | 61172.89% |
2010 | 14.34 Million USD | 0.0% |
2009 | - USD | 0.0% |
2008 | - USD | -100.0% |
2007 | 2.01 Million USD | 18.17% |
2006 | 1.7 Million USD | 0.0% |
Year | Gross Profit | Gross Profit Growth |
---|---|---|
2022 Q2 | 567.89 Thousand USD | -11.84% |
2022 Q1 | 644.16 Thousand USD | -26.64% |
2022 Q3 | 501.11 Thousand USD | -11.76% |
2021 Q4 | 878.13 Thousand USD | 628.18% |
2021 Q2 | - USD | 0.0% |
2021 Q3 | 120.59 Thousand USD | 0.0% |
2021 FY | -488.31 Thousand USD | 0.0% |
2021 Q1 | - USD | 100.0% |
2020 Q4 | -63.25 Thousand USD | 0.0% |
2020 Q1 | - USD | 0.0% |
2020 Q2 | 63.25 Thousand USD | 0.0% |
2020 FY | - USD | 0.0% |
2020 Q3 | - USD | -100.0% |
2019 Q3 | - USD | 0.0% |
2019 FY | - USD | 0.0% |
2019 Q1 | - USD | 0.0% |
2019 Q2 | - USD | 0.0% |
2018 Q3 | - USD | 0.0% |
2018 FY | - USD | 0.0% |
2018 Q1 | - USD | 0.0% |
2018 Q2 | - USD | 0.0% |
2017 FY | - USD | 0.0% |
2017 Q2 | - USD | 0.0% |
2017 Q1 | - USD | 0.0% |
2017 Q3 | - USD | 0.0% |
2016 Q3 | - USD | 0.0% |
2016 Q2 | - USD | 0.0% |
2016 Q1 | - USD | 0.0% |
2016 FY | - USD | 0.0% |
2015 FY | - USD | 0.0% |
2015 Q3 | - USD | 0.0% |
2015 Q2 | - USD | 0.0% |
2015 Q1 | - USD | 0.0% |
2014 Q3 | - USD | 0.0% |
2014 Q1 | - USD | 0.0% |
2014 FY | - USD | 0.0% |
2014 Q2 | - USD | 0.0% |
2013 Q3 | - USD | 0.0% |
2013 Q2 | - USD | 0.0% |
2013 FY | - USD | 0.0% |
2013 Q1 | - USD | 0.0% |
2012 Q3 | - USD | 0.0% |
2012 Q2 | - USD | 0.0% |
2012 Q1 | - USD | 0.0% |
2012 FY | - USD | -100.0% |
2011 Q3 | - USD | 0.0% |
2011 Q1 | - USD | 0.0% |
2011 FY | 8.79 Billion USD | 61172.89% |
2011 Q2 | - USD | 0.0% |
2010 Q3 | - USD | 0.0% |
2010 FY | 14.34 Million USD | 0.0% |
2010 Q1 | - USD | 0.0% |
2010 Q2 | - USD | 0.0% |
2009 FY | - USD | 0.0% |
2009 Q2 | - USD | 0.0% |
2009 Q1 | - USD | 0.0% |
2009 Q3 | - USD | 0.0% |
2008 Q1 | - USD | 0.0% |
2008 FY | - USD | -100.0% |
2008 Q3 | - USD | 0.0% |
2008 Q2 | - USD | 0.0% |
2007 Q3 | - USD | 0.0% |
2007 Q1 | 321.44 Thousand USD | 0.0% |
2007 FY | 2.01 Million USD | 18.17% |
2007 Q2 | - USD | -100.0% |
2006 FY | 1.7 Million USD | 0.0% |
2006 Q2 | - USD | 0.0% |
2006 Q3 | - USD | 0.0% |
Name | Gross Profit | Gross Profit Difference |
---|---|---|
America Great Health | 168.58 Thousand USD | 389.649% |
Ampio Pharmaceuticals, Inc. | -250 Thousand USD | -95.326% |
Aridis Pharmaceuticals, Inc. | - USD | Infinity% |
Biora Therapeutics, Inc. | -551 Thousand USD | 11.377% |
Bio-Path Holdings, Inc. | -178 Thousand USD | -174.334% |
Better Therapeutics, Inc. | -2.72 Million USD | 82.106% |
Calithera Biosciences, Inc. | -1.38 Million USD | 64.743% |
Comera Life Sciences Holdings, Inc. | 422.71 Thousand USD | 215.519% |
Gene Biotherapeutics, Inc. | - USD | Infinity% |
eFFECTOR Therapeutics, Inc. | -22.91 Million USD | 97.869% |
Eloxx Pharmaceuticals, Inc. | - USD | Infinity% |
Evelo Biosciences, Inc. | - USD | Infinity% |
Evolutionary Genomics, Inc. | -1.02 Million USD | 52.196% |
Finch Therapeutics Group, Inc. | -7.09 Million USD | 93.115% |
Galera Therapeutics, Inc. | -259 Thousand USD | -88.538% |
Innovation1 Biotech Inc. | -52.69 Thousand USD | -826.627% |
Kiromic BioPharma, Inc. | -2.79 Million USD | 82.535% |
Molecular Templates, Inc. | 50.39 Million USD | 100.969% |
Navidea Biopharmaceuticals, Inc. | -119.29 Thousand USD | -309.333% |
NexImmune, Inc. | -1.02 Million USD | 52.358% |
Orgenesis Inc. | -5.72 Million USD | 91.47% |
Panbela Therapeutics, Inc. | -25.64 Million USD | 98.096% |
Point of Care Nano-Technology, Inc. | -4601.00 USD | -10513.215% |
PaxMedica, Inc. Common Stock | - USD | Infinity% |
Scopus BioPharma Inc. | - USD | Infinity% |
Sorrento Therapeutics, Inc. | 29.38 Million USD | 101.662% |
TRACON Pharmaceuticals, Inc. | -232 Thousand USD | -110.48% |
Trevena, Inc. | 1.45 Million USD | 133.561% |
Vaxxinity, Inc. | -2.23 Million USD | 78.142% |
Vaccinex, Inc. | -16 Million USD | 96.949% |
Vicapsys Life Sciences, Inc. | - USD | Infinity% |
Viracta Therapeutics, Inc. | -492 Thousand USD | 0.749% |
ZIVO Bioscience, Inc. | 11.61 Thousand USD | 4305.978% |